CXCL5 and idiopathic pulmonary fibrosis: The accumulation of acetyl-CoA further influences the lipid metabolism of CAFs by reprogramming the CXCL5–CXCR2 axis.[52] It is therefore speculated that the increased risk of IPF associated with Isovalerylcarnitine (C5) may be attributed to the disruption of lipid metabolism in CAFs through the regulation of key genes in the lipid metabolism pathway.